Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

New data presented by Amgen at the 2022 AAD Congress reinforced the efficacy of apremilast in patients with mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis. This announcement follows the recent US Food and Drug Administration (FDA) expanded Otezla label approval which enabled the use of Otezla across all levels of disease severity. Otezla is the first and only oral therapy FDA approved in adult patients with mild, moderate, and severe plaque psoriasis.

Read full press release

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now

  


IPC STATEMENT
on SARS-CoV-2 Vaccines and Psoriasis
 

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.

READ FULL STATEMENT


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK